Junko Oshima

Junko Oshima

Auto-generated profile, based on publicly available information

Junko Oshima

Department of Laboratory Medicine and Pathology University of Washington Seattle Washington USA

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Ageing Research Reviews
Verified
Journal Article
Closed access
JOJunko Oshima
Junko Oshima
JSJulia M. Sidorova
Julia M. Sidorova
RMRaymond J. Monnat
Raymond J. Monnat

3 May 2006 in Human Mutation
Verified
Journal Article
Open access
PDF file
SHShurong Huang
Shurong Huang
LLLin Lee
Lin Lee
NHNancy B. Hanson
Nancy B. Hanson
CLCatherine Lenaerts
Catherine Lenaerts
HHHolger Hoehn
Holger Hoehn
JOJunko Oshima
Junko Oshima
The International Registry of Werner syndrome (www.wernersyndrome.org) has been providing molecular diagnosis of the Werner syndrome (WS) for the past decade. The present communication summarizes, from among 99 WS subjects, the spectrum of 50 distinct mutations discovered by our group and by others since the WRN gene (also called RECQL2 or REQ3) was first cloned in 1996; 25 of these have not previously been published. All WRN mutations reported thus far have resulted in the elimination of the nuclear localization signal at the C‐terminus of the protein, precluding functional interactions in the nucleus; thus, all could be classified as null mutations. We now report two new mutations in the N‐terminus that result in instability of the WRN protein. Clinical data confirm that the most penetrant phenotype is bilateral ocular cataracts. Other cardinal signs were seen in more than 95% of the cases. The median age of death, previously reported to be in the range of 46–48 years, is 54 years. Lymphoblastoid cell lines (LCLs) have been cryopreserved from the majority of our index cases, including material from nuclear pedigrees. These, as well as inducible and complemented hTERT (catalytic subunit of human telomerase) immortalized skin fibroblast cell lines are available to qualified investigators. Hum Mutat 27(6), 558–567, 2006. Published 2006 Wiley‐Liss, Inc.

23 July 2003 in Aging Cell
Verified
Journal Article
Open access
PDF file
LCLishan Chen
Lishan Chen
SHShurong Huang
Shurong Huang
LLLin Lee
Lin Lee
ADAlbert Davalos
Albert Davalos
RSRobert H. Schiestl
Robert H. Schiestl
JOJunko Oshima
Junko Oshima
Summary: Werner syndrome (WS) predisposes patients to cancer and premature aging, owing to mutations in WRN. The WRN protein is a RECQ‐like helicase and is thought to participate in DNA double‐strand break (DSB) repair by non‐homologous end joining (NHEJ) or homologous recombination (HR). It has been previously shown that non‐homologous DNA ends develop extensive deletions during repair in WS cells, and that this WS phenotype was complemented by wild‐type (wt) WRN. WRN possesses both 3′ → 5′ exonuclease and 3′ → 5′ helicase activities. To determine the relative contributions of each of these distinct enzymatic activities to DSB repair, we examined NHEJ and HR in WS cells (WRN–/–) complemented with either wtWRN, exonuclease‐defective WRN (E–), helicase‐defective WRN (H–) or exonuclease/helicase‐defective WRN (E–H–). The single E– and H– mutants each partially complemented the NHEJ abnormality of WRN–/– cells. Strikingly, the E–H– double mutant complemented the WS deficiency nearly as efficiently as did wtWRN. Similarly, the double mutant complemented the moderate HR deficiency of WS cells nearly as well as did wtWRN, whereas the E– and H– single mutants increased HR to levels higher than those restored by either E–H– or wtWRN. These results suggest that balanced exonuclease and helicase activities of WRN are required for optimal HR. Moreover, WRN appears to play a structural role, independent of its enzymatic activities, in optimizing HR and efficient NHEJ repair. Another human RECQ helicase, BLM, suppressed HR but had little or no effect on NHEJ, suggesting that mammalian RECQ helicases have distinct functions that can finely regulate recombination events.

30 May 2022 in Aging Cell
Verified
Journal Article
Open access
RKRenuka Kandhaya‐Pillai
Renuka Kandhaya‐Pillai
XYXiaomeng Yang
Xiaomeng Yang
TTTamar Tchkonia
Tamar Tchkonia
GMGeorge M. Martin
George M. Martin
JKJames L. Kirkland
James L. Kirkland
JOJunko Oshima
Junko Oshima
Older age and underlying conditions such as diabetes/obesity or immunosuppression are leading host risk factors for developing severe complications from COVID‐19 infection. The pathogenesis of COVID‐19‐related cytokine storm, tissue damage, and fibrosis may be interconnected with fundamental aging processes, including dysregulated immune responses and cellular senescence. Here, we examined effects of key cytokines linked to cellular senescence on expression of SARS‐CoV‐2 viral entry receptors. We found exposure of human umbilical vein endothelial cells (HUVECs) to the inflammatory cytokines, TNF‐α + IFN‐γ or a cocktail of TNF‐α + IFN‐γ + IL‐6, increased expression of ACE2/DPP4, accentuated the pro‐inflammatory senescence‐associated secretory phenotype (SASP), and decreased cellular proliferative capacity, consistent with progression towards a cellular senescence‐like state. IL‐6 by itself failed to induce substantial effects on viral entry receptors or SASP‐related genes, while synergy between TNF‐α and IFN‐γ initiated a positive feedback loop via hyper‐activation of the JAK/STAT1 pathway, causing SASP amplification. Breaking the interactive loop between senescence and cytokine secretion with JAK inhibitor ruxolitinib or antiviral drug remdesivir prevented hyper‐inflammation, normalized SARS‐CoV‐2 entry receptor expression, and restored HUVECs proliferative capacity. This loop appears to underlie cytokine‐mediated viral entry receptor activation and links with senescence and hyper‐inflammation.

1 August 1999 in Molecular Biology of the Cell
Verified
Journal Article
Closed access
ABAdayabalam S. Balajee
Adayabalam S. Balajee
AMAmrita Machwe
Amrita Machwe
AMAlfred May
Alfred May
MGMatthew D. Gray
Matthew D. Gray
JOJunko Oshima
Junko Oshima
VBVilhelm A. Bohr
Vilhelm A. Bohr
Werner syndrome (WS) is a human progeroid syndrome characterized by the early onset of a large number of clinical features associated with the normal aging process. The complex molecular and cellular phenotypes of WS involve characteristic features of genomic instability and accelerated replicative senescence. The gene involved (WRN) was recently cloned, and its gene product (WRNp) was biochemically characterized as a helicase. Helicases play important roles in a variety of DNA transactions, including DNA replication, transcription, repair, and recombination. We have assessed the role of the WRN gene in transcription by analyzing the efficiency of basal transcription in WS lymphoblastoid cell lines that carry homozygous WRN mutations. Transcription was measured in permeabilized cells by [3H]UTP incorporation and in vitro by using a plasmid template containing the RNA polymerase II (RNA pol II)–dependent adenovirus major late promoter. With both of these approaches, we find that the transcription efficiency in different WS cell lines is reduced to 40–60% of the transcription in cells from normal individuals. This defect can be complemented by the addition of normal cell extracts to the chromatin of WS cells. Addition of purified wild-type WRNp but not mutated WRNp to the in vitro transcription assay markedly stimulates RNA pol II–dependent transcription carried out by nuclear extracts. A nonhelicase domain (a direct repeat of 27 amino acids) also appears to have a role in transcription enhancement, as revealed by a yeast hybrid–protein reporter assay. This is further supported by the lack of stimulation of transcription when mutant WRNp lacking this domain was added to the in vitro assay. We have thus used several approaches to show a role for WRNp in RNA pol II transcription, possibly as a transcriptional activator. A deficit in either global or regional transcription in WS cells may be a primary molecular defect responsible for the WS clinical phenotype.

1 January 2008 in Experimental Cell Research
Verified
Journal Article
Closed access
SHShurong Huang
Shurong Huang
RRRosa Ana Risques
Rosa Ana Risques
GMGeorge M. Martin
George M. Martin
PRPeter S. Rabinovitch
Peter S. Rabinovitch
JOJunko Oshima
Junko Oshima